Watch the webcasts from our industry partners' Satellite Symposia.
28 Mar 2025
Johnson & Johnson:
Transforming clinical practice in EGFR-mutant NSCLC
Coming soon
- Welcome and introductions
Nicolas Girard - Guiding treatment options for common EGFR-mutant NSCLC
Raffaele Califano - Optimising management for patients with common EGFR mutations
Vincent Sibaud - Discussion
- Closing remarks
Natasha Leighl
Pfizer:
Promising new targets and ADCs in development for NSCLC
- Welcome and introduction
David Planchard - Are we making progress? Updates on late-stage ADCs in NSCLC
David Planchard - What’s next in NSCLC? New targets and ADC innovations
Anna R. Minchom - Conclusions and panel discussion
David Planchard, Anna R. Minchom
touchIME:
Navigating the clinical impact of TROP2-targeting in NSCLC
- The emergence of TROP2 in NSCLC
Marina C. Garassino - Clinical impact of targeting TROP2 in NSCLC
Jarushka Naidoo - Clinical utility of TROP2 expression in NSCLC
David Planchard - Managing ADC toxicities in NSCLC clinical practice
Marina C. Garassino, Jarushka Naidoo, David Planchard - Future directions for TROP2 in NSCLC
Marina C. Garassino